Sarepta Therapeutics (SRPT) Retained Earnings (2010 - 2026)
Sarepta Therapeutics' quarterly Retained Earnings came in at -$121000.0 in Q1 2026, down 455.88% year-on-year from $34000.0 in Q1 2025, and down 144.49% quarter-over-quarter from $272000.0 in Q4 2025.
Sarepta Therapeutics has reported Retained Earnings for 17 years, with the latest figure at -$121000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 455.88% year-over-year to -$121000.0; the trailing twelve-month figure through Mar 2026 stood at -$121000.0 (down 455.88% YoY), and the FY2025 full-year result was $272000.0, up 224.77% from the prior year.
- Retained Earnings for Q1 2026 stood at -$121000.0, down from $272000.0 in the prior quarter.
- The five-year high for Retained Earnings was $918000.0 in Q4 2023, with the low at -$4.5 billion in Q2 2025.
- Average Retained Earnings over 5 years is -$1.5 billion, with a median of -$638000.0 recorded in 2023.
- Year-over-year, Retained Earnings plunged 177162800.0% in 2022 and jumped 224.77% in 2025.
- Tracing SRPT's Retained Earnings over 5 years: stood at -$3.9 billion in 2022, then jumped by 100.02% to $918000.0 in 2023, then slumped by 123.75% to -$218000.0 in 2024, then jumped by 224.77% to $272000.0 in 2025, then sank by 144.49% to -$121000.0 in 2026.
- The last three Retained Earnings figures came in at -$121000.0 (Q1 2026), $272000.0 (Q4 2025), and $220000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | -121,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -121,000.00 |
| Dec 31, 2025 | 272,000.00 |
| Sep 30, 2025 | 220,000.00 |
| Jun 30, 2025 | -4.46 Bn |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | -218,000.00 |
| Sep 30, 2024 | -4.37 Bn |
| Jun 30, 2024 | -1.03 Mn |
| Mar 31, 2024 | -4.41 Bn |
| Dec 31, 2023 | 918,000.00 |
| Sep 30, 2023 | -638,000.00 |
| Jun 30, 2023 | -4.45 Bn |
| Mar 31, 2023 | -419,000.00 |
| Dec 31, 2022 | -3.91 Bn |
| Sep 30, 2022 | -3.21 Mn |
| Jun 30, 2022 | -3.54 Bn |
| Mar 31, 2022 | -306,000.00 |
| Dec 31, 2021 | -20,000.00 |
| Sep 30, 2021 | -3.08 Bn |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | -2.96 Bn |
| Dec 31, 2020 | 3,000.00 |
| Sep 30, 2020 | -2.66 Bn |
| Jun 30, 2020 | -2.46 Bn |
| Mar 31, 2020 | 624,000.00 |
| Dec 31, 2019 | -2.29 Bn |
| Sep 30, 2019 | 75,000.00 |
| Jun 30, 2019 | 82,000.00 |
| Mar 31, 2019 | 19,000.00 |
| Dec 31, 2018 | -99,000.00 |
| Sep 30, 2018 | 8,000.00 |
| Jun 30, 2018 | -361,000.00 |
| Mar 31, 2018 | -643,000.00 |
| Dec 31, 2017 | -379,000.00 |
| Sep 30, 2017 | -1.19 Bn |
| Jun 30, 2017 | -1.15 Bn |
| Mar 31, 2017 | -55,000.00 |
| Dec 31, 2016 | -1.17 Bn |
| Sep 30, 2016 | -1.08 Bn |
| Jun 30, 2016 | -1.02 Bn |
| Mar 31, 2016 | -5,000.00 |
| Dec 31, 2015 | -111,000.00 |
| Sep 30, 2015 | -834.37 Mn |
| Jun 30, 2015 | -782.44 Mn |
| Mar 31, 2015 | -740.58 Mn |
| Dec 31, 2014 | -95,000.00 |
| Sep 30, 2014 | -634.61 Mn |
| Jun 30, 2014 | -605.38 Mn |
| Mar 31, 2014 | 571.51 Mn |
| Dec 31, 2013 | -543.24 Mn |
| Sep 30, 2013 | 534.42 Mn |
| Jun 30, 2013 | 492.39 Mn |
| Mar 31, 2013 | 473.34 Mn |
| Dec 31, 2012 | 431.25 Mn |
| Mar 31, 2012 | 327.67 Mn |
| Dec 31, 2011 | 309.96 Mn |
| Sep 30, 2011 | 308.55 Mn |
| Jun 30, 2011 | 304.53 Mn |
| Dec 31, 2010 | 307.65 Mn |